Exhibit C-1

30(b)(6) Abbott (Sellers, Michael)

March 16, 2008

Page 1

THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

In re: PHARMACEUTICAL) MDL NO. 1456

INDUSTRY AVERAGE WHOLESALE) CIVIL ACTION

PRICE LITIGATION) 01-CV-12257-PBS

Videotaped Rule 30(b)(6) Deposition of MICHAEL SELLERS, at 77 West Wacker Drive, Chicago, Illinois, commencing at 9:00 a.m. on Sunday, March 16, 2008, before Donna M. Kazaitis, RPR, CSR No. 084-003145.

```
Page 179
 1
     people that understood or thought they understood
 2
     that there was a relationship.
                     That knowledge expanded primarily
     due to these, the litigation in the late 1990s.
 5
     BY MS. ST. PETER-GRIFFITH:
 6
               Did Abbott at any time make any inquiry
         Ο.
     of any government official, state or federal, to
     seek clarification of the relationship between its
 9
     price reporting or AWPs and Medicare or Medicaid
10
     reimbursement?
11
               MS. TABACCHI:
                               Object to the form.
12
                    Would you mind reading that back.
13
                     (WHEREUPON said record was read
14
                     back as requested.)
15
                               Object to the form,
               MS. TABACCHI:
16
     beyond the scope of the Notice.
17
               THE WITNESS:
                              I don't believe that was,
18
     I'm not aware of any communication to that effect.
19
                     I am aware that there was ongoing
20
     communication between the reimbursement folks and
     the carriers to understand what they could about
22
     what we were getting paid for our clients, but I
```

Page 180

- don't think that's what you're asking about.
- BY MS. ST. PETER-GRIFFITH:
- Q. No. I'm not asking about individual
- reimbursement questions posed by the reimbursement
- ⁵ department within Home Infusion, unless they made
- the inquiry to Medicare and Medicaid about the
- relationship between Abbott's AWPs or Abbott's
- 8 reported pricing and Medicare and Medicaid
- 9 reimbursement. Are you aware of any inquiry by
- Home Infusion to that effect?
- MS. TABACCHI: Object to the form.
- BY MS. ST. PETER-GRIFFITH:
- 13 Q. Or is Abbott aware of any -- I want to
- make clear, sir, that I'm expecting that you're
- answering on behalf of Abbott.
- A. I would expect that to be a natural
- communication to either the Medicaid agency. If
- you had any questions about how you got
- reimbursed, that would be a natural question to
- inquire as to why the reimbursement was high, low,
- in between.
- So I don't doubt that there were

```
Page 183
```

- MS. ST. PETER-GRIFFITH: That's okay,
- Tina. Any time you can speed things up, please
- feel free. (Laughter.)
- MS. TABACCHI: I knew that's not what
- you meant to ask.
- 6 MS. ST. PETER-GRIFFITH: That is not
- ⁷ what I meant to ask. Thank you.
- 8 BY MS. ST. PETER-GRIFFITH:
- ⁹ Q. When did Abbott first notice those
- disparities?
- MS. TABACCHI: Objection, asked and
- ¹² answered.
- THE WITNESS: I can only tell you that
- we looked at a number of products in the fall of
- ¹⁵ 2000.
- BY MS. ST. PETER-GRIFFITH:
- Q. At any time prior to 2001 for the time
- period from '91 through 2001, did Abbott ever
- notify any state or federal official about these
- inadvertent disparities?
- MS. TABACCHI: Object to the form,
- beyond the scope of the Notice.

Henderson Legal Services, Inc.

```
Page 184
 1
                MS. ST. PETER-GRIFFITH: It's not beyond
 2
     the scope of the Notice.
 3
                THE WITNESS:
                              No.
     BY MS. ST. PETER-GRIFFITH:
 5
         Ο.
               How come?
 6
                MS. TABACCHI:
                               Same objections.
 7
                THE WITNESS: We would have seen no
 8
     reason to involve a government agency in what we
 9
     considered to be internal issues.
10
     BY MS. ST. PETER-GRIFFITH:
11
               Well, did you have an understanding as
         0.
12
     to whether what you've called inadvertent
13
     disparities caused overpayments or false claims to
     be submitted, overpayments to be made by or false
14
15
     claims to be submitted by the Medicare and
16
     Medicaid programs?
17
               MS. TABACCHI:
                               Object to the form,
18
     beyond the scope of the Notice, calls for a legal
19
     conclusion.
20
               THE WITNESS: Again, I can't rule on
21
     false claims.
22
     BY MS. ST. PETER-GRIFFITH:
```

Page 310

- ¹ be.
- BY MS. ST. PETER-GRIFFITH:
- Q. If you could move on -- oh, let me ask
- you, at any time from 1991 until 2001 did Abbott
- ever notify any state or federal official about
- what its actual contract prices were that it was
- ⁷ charging its customers?
- MS. TABACCHI: Object to the form,
- beyond the scope of the Notice.
- MS. ST. PETER-GRIFFITH: No, it's not.
- THE WITNESS: It was not our
- understanding that that was a requirement of any
- entity.
- We thought the government had a
- good picture of our nonlist price prices. They
- had quarterly publications of our AMP, they had
- our Federal Supply Schedule prices, we had prices
- negotiated with the DOD.
- So we thought if a government
- agency needed it, it was within the government
- ²¹ agency's purview already.
- BY MS. ST. PETER-GRIFFITH:

Henderson Legal Services, Inc.